Comparison between Artivion (NYSE: AORT) and TELA Bio (NASDAQ: TELA)


Artivion (NYSE:AORT – Get Rating) and TELA Bio (NASDAQ:TELA – Get Rating) are both small-cap medical companies, but which is the best investment? We’ll compare the two companies based on institutional ownership strength, analyst recommendations, dividends, profitability, earnings, risk and valuation.

Risk and Volatility

Artivion has a beta of 1.42, which means its price is 42% more volatile than the S&P 500. In comparison, TELA Bio has a beta of 1.44, which means its price is 44% more volatile than the S&P500.

Valuation and benefits

This table compares the revenue, earnings per share (EPS) and valuation of Artivion and TELA Bio.

Gross revenue Price/sales ratio Net revenue Earnings per share Price/earnings ratio
Artivion $298.84 million 2.64 -$14.83 million ($0.39) -50.26
TELA Bio $29.46 million 3.99 -$33.28 million ($2.48) -3.25

Artivion has higher revenue and profit than TELA Bio. Artivion trades at a lower price-to-earnings ratio than TELA Bio, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of the current ratings and recommendations for Artivion and TELA Bio, as provided by MarketBeat.com.

Sales Ratings Hold odds Buy reviews Strong buy odds Rating
Artivion 0 1 2 0 2.67
TELA Bio 0 0 2 0 3.00

Artivion currently has a consensus price target of $27.00, suggesting a potential upside of 37.76%. TELA Bio has a consensus price target of $19.50, suggesting a potential upside of 141.64%. Given TELA Bio’s stronger consensus rating and higher possible upside, analysts clearly believe TELA Bio is more favorable than Artivion.

Institutional and insider ownership

81.0% of Artivion shares are held by institutional investors. 5.6% of Artivion shares are held by insiders. Comparatively, 5.7% of TELA Bio shares are held by insiders. Strong institutional ownership indicates that large fund managers, endowments, and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares the net margins, return on equity and return on assets of Artivion and TELA Bio.

Net margins Return on equity return on assets
Artivion -4.95% 3.08% 1.16%
TELA Bio -113.15% -155.13% -55.28%

Summary

Artivion beats TELA Bio on 7 of the 13 factors compared between the two stocks.

About Artivion

(Get an assessment)

Artivion Inc. manufactures, processes and distributes medical devices and implantable human tissues worldwide. The Company offers BioGlue, a polymer composed of bovine blood proteins and a protein cross-linking agent for cardiac, vascular, neurological and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and E-vita Open Plus and E-vita Open Neo. It also provides engineered E-xtra design systems for the treatment of aortic vascular disease; E-nside, a ready-to-use stent for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-nya, a thoracic stent system for the minimally invasive repair of descending aortic lesions; E-ventus BX, a peripheral balloon-expandable stent graft for endovascular treatment of the renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries and aneurysmal iliac side branches; and E-tegra, an abdominal aortic aneurysm stent system. Additionally, the company offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powder hemostat for use in surgical procedures; cardiac laser therapy products for the treatment of angina pectoris; CryoVein Femoral Vein and CryoArtery Femoral Artery Vascular Preservation Services; On-X aortic and mitral heart valve prostheses and the On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures for mitral cord replacement; and ascyrus medical dissection stents, as well as pyrolytic carbon coating services to medical device manufacturers. It serves physicians, hospitals and other healthcare facilities, as well as cardiac, vascular, thoracic and general surgeons. The company was formerly known as CryoLife, Inc. and changed its name to Artivion Inc. in January 2022. The company was founded in 1984 and is headquartered in Kennesaw, Georgia.

About TELA Bio

(Get an assessment)

TELA Bio, Inc., a commercial-stage medical technology company, is focused on providing soft tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of patient anatomy. It offers a portfolio of OviTex (OviTex) tissue-enhanced matrix products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix to address unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile ovine rumen-derived reinforced tissue matrix with polypropylene fiber for use in laparoscopic surgery and robot-assisted surgical repairs of hernias. The company markets its products through a single direct sales force, primarily in the United States. TELA Bio, Inc. was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.



Get news and reviews for Artivion Daily – Enter your email address below to receive a concise daily summary of the latest news and analyst ratings for Artivion and related companies with MarketBeat.com’s FREE daily newsletter.

Comments are closed.